Cancer Genetics

癌症遗传学

基本信息

批准号：
8340215
负责人：
TERRY R MAGNUSON
金额：
$ 18.77万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-05-23 至 2015-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8340215
关键词：
Area Award BRCA1 gene Basic Science Bioinformatics Biological Biological Assay Biological Models Cancer Center Cells Chromatin Clinical Clinical Sciences Colorectal Cancer Core Facility DNA Databases Development Diagnosis Disease Early Diagnosis Engineering Ensure Environment Epigenetic Process Extramural Activities Faculty Family Functional RNA Funding Genes Genetic Genetic Predisposition to Disease Genetic Programming Genetic Research Genetic Transcription Genome Genomics Genotype Goals Grant Human Human Genetics Human Genome Individual International Investigation Investments Laboratories Laboratory Organism Lead Lesion Malignant Neoplasms Metabolism Minority Molecular Molecular Analysis Monitor Mouse Models of Human Cancer Consortium Multiple Abnormalities Mus National Cancer Institute Neoplasm Metastasis Nobel Prize Nutritional Pathway interactions Penetrance Phase Phenotype Pilot Projects Population Population Sciences Predisposition Process Program Development Randomized Regulation Research Research Infrastructure Research Peer Review Research Personnel Role Scientist System Technology The Cancer Genome Atlas Variant Vision Work Yeasts base cancer epidemiology cancer genetics cancer therapy career clinical application clinical care disease-causing mutation genetic analysis genetic technology genome-wide insight meetings mouse genome mouse model mutant next generation non-genetic novel novel strategies patient oriented population based pre-clinical programs recombinational repair technology development tool tumor uncontrolled cell growth

项目摘要

Cancer Genetics: The goal of the program is to take cancer genetics research beyond the standard genotype-phenotype correlation toward understanding cross talk between genes and non-genetic influences on genes (systems genetics). Genes do not act in isolation and these types of interactions impact the resulting phenotype with profound implications in human cancer. Program faculty have outlined five strategic goals: (i) Genome-wide strategies, (ii) High penetrance cancer genes, (iii) Loss of genome integrity, (iv) Epigenetic processes, and (v) State-of-the-art infrastructure, both technology and bioinformatics. The Program is achieving their goals through program and program subset meetings, collaborative grants, cancer center investment in recruitment, technology development and pilot project funding. Highlights of research by Program investigators include creation of a novel mouse platform known as the Collaborative Cross, which randomizes the mouse genome to mimic human variation (Pardo Manuel de Villena, Threadgill, Pomp, Wang, Valdar). Perou and Sharpless have created the mouse phase I unit of genetically engineered pre-clinical mouse models for monitoring and developing phenotypic assays for cancer treatment. Evans and Berg have expanded the clinical genetics program and have embarked on a patient-centered project aimed at using next-generation genetic technology to look for disease-causing mutations in families where a Mendelian cancer susceptibility was suspected but not discovered. Threadgill and Pomp are part of the Mouse Models of Human Cancer Consortium with a project that focuses on colorectal cancer. Lieb continues to develop novel genomic approaches and Magnuson has challenged a long-standing epigenetic role for the non-coding RNA known as Xist. Proudly, Oliver Smithies was awarded the Nobel Prize for his pioneering work that underlies the program's use of cancer mouse models. Recruitment in statistical and human genetics, as well as computational approaches, has expanded the scope of the program, particularly its impact on the population and clinical sciences. Core facility development of high throughput sequencing has provided additional opportunities for participation in high priority NCI initiatives, e.g., phase II of the Cancer Genome Atlas (Perou, Chiang, Wright and Hayes). In 2009, the 39 program faculty investigators have 78 grants and $32.8 million (total $) in extramural support. Peer-reviewed research funding totals 62 grants and $29.7 million (total $), including 18 grants ($9.0 million) from the National Cancer Institute.

癌症遗传学：该程序的目的是将癌症遗传学研究超出标准基因型 - 表型相关性，以了解基因与非基因对基因的非遗传影响之间的交流（系统遗传学）。基因不孤立起作用，这些类型的相互作用影响了由此产生的表型，对人类癌症产生了深远的影响。课程教师概述了五个战略目标：（i）全基因组策略，（ii）高渗透癌基因，（iii）基因组完整性的丧失，（iv）表观遗传过程以及（v）技术和生物信息学的最先进的基础设施。该计划是通过计划和计划子集会议，协作赠款，招聘癌症中心投资，技术开发和试点项目资金来实现其目标。计划调查人员的研究亮点包括创建一个名为“协作十字”的新型小鼠平台，该平台将小鼠基因组随机与模仿人类变异（Pardo Manuel de Villena，Threadgill，Pomp，Pomp，Wang，Valdar）。 Perou和Sharpless创建了基因工程前小鼠模型的小鼠I期单位，用于监测和开发用于癌症治疗的表型测定。埃文斯（Evans）和伯格（Berg）扩大了临床遗传学计划，并着手进行以患者为中心的项目怀疑孟德尔癌敏感性但未发现的家庭的家庭突变。 Theadgill和POMP是人类癌联盟小鼠模型的一部分，该项目的重点是结直肠癌。 Lieb继续开发出新的基因组方法，而Magnuson挑战了被称为Xist的非编码RNA的长期表观遗传作用。自豪地，奥利弗·史密斯（Oliver Smithies）被授予诺贝尔奖的开创性工作是该计划使用癌症老鼠模型的基础。统计和人类遗传学以及计算方法的招募，扩大了该计划的范围，尤其是其对人群和临床科学的影响。高通量测序的核心设施发展为参与高优先级NCI计划的更多机会，例如癌症基因组地图集（Perou，Chiang，Wright和Hayes）的II期。 2009年，这位39名计划教师的调查员获得了78个赠款和3280万美元（总$）的校外支持。同行评审的研究资金总计62赠款和2970万美元（总计$），其中包括来自国家癌症研究所的18笔赠款（900万美元）。